Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy

Area of Science:

• Endocrinology
• Cardiology
• Metabolic Disorders

Background:

• Lipodystrophy syndromes are rare genetic disorders characterized by adipose tissue deficiency, leading to severe metabolic complications like left ventricular (LV) hypertrophy.
• Mechanisms contributing to LV hypertrophy in lipodystrophy include hyperglycemia, dyslipidemia, and hyperinsulinemia.

Purpose of the Study:

• To investigate the effects of recombinant leptin (metreleptin) on cardiac structure and function in patients with generalized lipodystrophy (GLD) and partial lipodystrophy (PLD).

Main Methods:

• An open-label study involving 38 lipodystrophy patients (18 GLD, 20 PLD) treated with metreleptin.
• Evaluations included echocardiograms, blood pressure, triglycerides, A1c, and insulin resistance (HOMA-IR) at baseline, 1 year, and 3-5 years.

Main Results:

• Metreleptin significantly reduced triglycerides, A1c, and HOMA-IR in GLD patients.
• Cardiac parameters improved in GLD, with reduced posterior wall thickness, LV mass, and increased septal e' velocity.
• Only HOMA-IR improved in PLD patients, with no significant cardiac changes observed.

Conclusions:

• Metreleptin treatment attenuated cardiac hypertrophy and improved diastolic function (septal e' velocity) in GLD, likely through reduced lipotoxicity and glucose toxicity.
• The cardiac benefits observed in GLD may be linked to metabolic improvements, but further research is needed for leptin-sufficient populations.